Two New Active Ingredients against Alpha-Synucleins are being tested in Clinical Studies
Two other active ingredients against increased alpha synucleins, a suspected cause of Parkinson’s disease, developments being funded by the Michael J. Fox Foundation, have entered clinical trials (tests on people).
Now, after successful laboratory and animal tests, it can be tested whether these active ingredients are on the one hand safe for humans and on the other whether they have the desired therapeutic effect on Parkinson’s patients. The active ingredients concerned are NPT200-11 by Neuropore Therapies and BIIB-054 by Biogen. More here on their method of working and the current press release.